To what extent are we confident that tapentadol induces less constipation and other side effects than the other opioids in chronic pain patients? a confidence evaluation in network meta-analysis

Abstract

Background:

A confidence evaluation helps to make informed decisions about the results of meta-analyses. The goal of this work is to perform a confidence evaluation of results of a network meta-analysis (NMA) on the digestive side effects of tapentadol in patients with chronic pain.

Methods:

An updated search in PubMed/Medline and Web of Science search until March 2020 was done to perform pairwise meta-analyses with NMA using random-effect models and confidence in network meta-analysis (CiNeMA) for the confidence analysis.

Results:

Twenty-five studies were included in the final analyses. Pairwise and indirect comparisons showed a reduced risk of constipation with tapentadol compared to oxycodone. The confidence evaluation did not raise any concerns in terms of confidence for the oxycodone versus tapentadol comparisons. The oxycodone-naloxone versus tapentadol comparisons showed some concerns, particularly in terms of imprecision and incoherence. Regarding the overall risk of any side effects, the confidence evaluation showed a major concern regarding imprecision, but not for the comparison between tapentadol and oxycodone. However, this comparison showed a major heterogeneity.

Discussion and conclusions:

A confidence evaluation in meta-analysis on the effect of tapentadol compared to other opioids in chronic pain showed possible imprecision, heterogeneity and/or incoherence. However, with a high level of confidence, tapentadol was associated with a lower incidence of constipation than oxycodone. Confidence analyses can help to get more information from meta-analyses.

Keywords

Tapentadol chronic pain confidence evaluation in network meta-analysis

Get full access to this article

View all access options for this article.

References

Meng

Acuff

, et al. Tolerability of opioid analgesia for chronic pain: a network meta-analysis. Sci Rep 2017; 7(1): 1995.

Serrie

Lange

Steup

Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Curr Med Res Opin 2017; 33(8): 1423–1432.

Salanti

Del Giovane

Chaimani

, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE 2014; 9(7): e99682.

Papakonstantinou

Salanti

CINeMA – Confidence in Network Meta-Analysis. Version 0.6. Bern: Institute of Social and Preventive Medicine, 2018, cinema.ispm.unibe.ch

Ahmedzai

Nauck

Bar-Sela

, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26(1): 50–60.

Allan

Hays

Jensen

, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322(7295): 1154–1158.

Allan

Richarz

Simpson

, et al. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine 2005; 30(22): 2484–2490.

Baron

Jansen

Binder

, et al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b/4 trial. Pain Pract 2016; 16(5): 600–619.

Binsfeld

Szczepanski

Waechter

, et al. A randomized study to demonstrate noninferiority of once-daily OROS(^®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10(5): 404–415.

10.

Etropolski

Kelly

Okamoto

, et al. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther 2011; 28(5): 401–417.

11.

Etropolski

Kuperwasser

Flügel

, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther 2014; 31(6): 604–620.

12.

Hale

Tudor

Khanna

, et al. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007; 29(5): 874–888.

13.

Hale

Upmalis

Okamoto

, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009; 25(5): 1095–1104.

14.

Hanna

Thipphawong

; the 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008; 7: 17.

15.

Hanna

Tuca

Thipphawong

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care 2009; 8: 14.

16.

Hartrick

Van Hove

Stegmann

, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009; 31(2): 260–271.

17.

Imanaka

Tominaga

Etropolski

, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013; 29(10): 1399–1409.

18.

Karlsson

Berggren

AC.

Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 2009; 31(3): 503–513.

19.

Leng

, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin J Pain 2015; 31(7): 612–620.

20.

Löwenstein

Leyendecker

Hopp

, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009; 10(4): 531–543.

21.

Matsumoto

Babul

Ahdieh

Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005; 6(5): 357–366.

22.

Nicholson

Ross

Sasaki

, et al. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006; 22(8): 1503–1514.

23.

Richarz

Waechter

Sabatowski

, et al. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Pain Pract 2013; 13(1): 30–40.

24.

Steiner

Munera

Hale

, et al. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain 2011; 12(11): 1163–1173.

25.

van Seventer

Smit

Schipper

, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003; 19(6): 457–469.

26.

Vondrackova

Leyendecker

Meissner

, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9(12): 1144–1154.

27.

Webster

Slevin

Narayana

, et al. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 2013; 14(9): 1332–1345.

28.

Shen

, et al. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain 2014; 15(8): 835–844.

29.

SAS Institute Inc. SAS/STAT^® 14.3 user’s guide. Cary, NC: SAS Institute Inc., 2017.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.06 MB